Literature DB >> 3088100

Species-restricted recognition of transfected HLA-A2 and HLA-B7 by human CTL clones.

S J Mentzer, J A Barbosa, J L Strominger, P A Biro, S J Burakoff.   

Abstract

Human cytolytic T lymphocytes (CTL) clones and HLA-A2- and HLA-B7-transfected human, monkey, and mouse cell lines were used to investigate the basis for species-restricted antigen recognition. Most allospecific CTL clones obtained after stimulation with the human JY cell line (source of HLA-A2 and HLA-B7 genomic clones) recognized HLA antigens expressed in human and monkey cell lines but did not recognize HLA expressed in murine cells. By initially stimulating the responder cells with HLA-transfected mouse cells, two CTL clones were obtained that recognized HLA expressed in murine cells. Functional inhibition of these CTL clones with anti-class I monoclonal antibodies (MAb) indicated that clones reactive with HLA+ murine cells were of higher avidity than clones that did not recognize HLA+ murine target cells. MAb inhibition of accessory molecule interactions demonstrated that the LFA-1 and T8 surface molecules were involved in CTL-target cell interactions in all three species. In contrast, the LFA-2/CD2 molecule, previously shown to participate in a distinct activation pathway, was involved in the cytolysis of transfected human and monkey target cells, but not in the lysis of HLA+ murine cells. Thus transfection of HLA genes into different recipient species cell lines provides us with the ability to additionally delineate the functional requirements for allospecific CTL recognition and lysis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3088100

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Limited regions of the alpha 2-domain alpha-helix control anti-A2 allorecognition: an analysis using a panel of A2 mutants.

Authors:  G Lombardi; M Matsui; R Moots; G Aichinger; S Sidhu; R Batchelor; J Frelinger; R Lechler
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

2.  Site-directed mutagenesis of an HLA-A3 gene identifies amino acid 152 as crucial for major-histocompatibility-complex-restricted and alloreactive cytotoxic-T-lymphocyte recognition.

Authors:  E P Cowan; M L Jelachich; J E Coligan; W E Biddison
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

3.  Alloreactivity studied with mutants of HLA-A2.

Authors:  J Santos-Aguado; M A Crimmins; S J Mentzer; S J Burakoff; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

4.  Human T-cell leukemia virus type I infection of CD4+ or CD8+ cytotoxic T-cell clones results in immortalization with retention of antigen specificity.

Authors:  D V Faller; M A Crimmins; S J Mentzer
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

5.  Generation and characterization of an HLA-DR alpha-specific monoclonal antibody using L-cell transfectants expressing human and mouse class II major histocompatibility dimers.

Authors:  D Palmer; M Kevany; C Mackworth-Young; R Batchelor; G Lombardi; R Lechler
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

6.  Site-directed mutagenesis of class I HLA genes. Role of glycosylation in surface expression and functional recognition.

Authors:  J A Barbosa; J Santos-Aguado; S J Mentzer; J L Strominger; S J Burakoff; P A Biro
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

7.  The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.

Authors:  M P Velders; C M van Rhijn; E Oskam; G J Fleuren; S O Warnaar; S V Litvinov
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

8.  Cytotoxic T lymphocytes from HLA-A2 transgenic mice specific for HLA-A2 expressed on human cells.

Authors:  E J Bernhard; A X Le; J A Barbosa; E Lacy; V H Engelhard
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.